Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Allergy and Asthma Reports
Published in: Current Allergy and Asthma Reports 1/2014

01-01-2014 | AUTOIMMUNITY (TK TARRANT, SECTION EDITOR)

Noninfectious Immune-Mediated Uveitis and Ocular Inflammation

Authors: Jennifer Pan, Manuj Kapur, Rex McCallum

Published in: Current Allergy and Asthma Reports | Issue 1/2014

Login to get access

Abstract

Noninfectious uveitis encompasses a diverse group of ocular inflammatory disorders that share an underlying immune etiology and may be associated with systemic disease or confined primarily to the eye. Uveitis is commonly classified by anatomical location of inflammation into anterior, intermediate, posterior, and panuveitis. The treatment of noninfectious uveitis consists of corticosteroids, immunosuppressive agents, and surgically placed steroid implants. We review the epidemiology, immunopathology, and clinical features of several noninfectious immune-mediated uveitides, including HLA-B27 acute anterior uveitis, juvenile idiopathic arthritis, intermediate uveitis, sarcoidosis, Behcet’s disease, Vogt-Koyanagi-Harada syndrome, sympathetic ophthalmia, and white dot syndromes. We also discuss the stepwise approach to medical treatment of immune-mediated uveitis as well as the characteristics, safety, and efficacy of immunosuppressive agents used to treat ocular inflammatory disease.
Literature
1.
Kempen JH, Altaweel MM, Holbrook JT, et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the Multicenter Uveitis Steroid Treatment (MUST) Trial. Ophthalmology. 2011;118:1916–26.PubMedCentralPubMedCrossRef
2.
Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80:332–6.PubMedCrossRef
3.
Chang JH, McCluskey PJ, Fracs F, Wakefield D. Acute anterior uveitis and HLA-B27. Surv Ophthalmol. 2005;50:364–88.PubMedCrossRef
4.
Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature (SUN) for reporting clinical data. -Results of the First International Workshop. Am J Ophthalmol. 2005;150:509–16.
5.
D’Alessandro LP, Forster DJ, Rao NA. Anterior uveitis and hypopyon. Am J Ophthalmol. 1991;112(3):317–21.PubMed
6.
Lyons JL, Rosenbaum JT. Uveitis associated with inflammatory bowel disease compared with uveitis associated with spondyloarthropathy. Arch Ophthalmol. 1997;115:61.PubMedCrossRef
7.
Paiva ES, Macaluso DC, Edwards A, Rosenbaum JT. Characterisation of uveitis in patients with psoriatic arthritis. Ann Rheum Dis. 2000;59:67.PubMedCrossRef
8.
Bayen H, Bayen MC, De Curzon HP, et al. Involvement of the posterior eye segment in HLA B27 (+) iridocyclitis. J Fr Ophthalmol. 1988;11:561–6.
9.
Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58(1):15–25.PubMedCrossRef
10.
Leak AM, Ansell BM, Burman SJ. Antinuclear antibody studies in juvenile chronic arthritis. Arch Dis Child. 1986;61:168–72.PubMedCrossRef
11.
Kotaniemi K, Savolainen A, Karma A, Aho K. Recent advances in uveitis of juvenile idiopathic arthritis. Surv Ophthalmol. 2003;48(5):489–502.PubMedCrossRef
12.
Gregory 2nd AC, Kempen JH, Daniel E, Kacmaz RO, Foster CS, et al. Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study. Ophthalmology. 2013;120:186–92.PubMedCentralPubMedCrossRef
13.
Ophthalmologic examinations in children with juvenile rheumatoid arthritis. Pediatrics. 2006; 117(5):1843–1845.
14.
Southward TR, Ryder CA. Ophthalmological screening in juvenile arthritis: should the frequency of screening be based on the risk of developing chronic iridocyclitis? Br J Rheumatol. 1992;31:633–4.CrossRef
15.
Henderly DE, Haymond RS, Rao NA, Smith RE. The significance of the pars plana exudates in pars planitis. Am J Ophthalmol. 1987;103:669–71.PubMed
16.
David JI, Mittal KK, Nussenblatt RB. HLA in intermediate uveitis. Dev Ophthalmol. 1992;23:35–7.
17.
Zein G, Berta A, Foster CS. Multiple sclerosis-associated uveitis. Ocul Immunol Inflamm. 2004;12:137.PubMedCrossRef
18.
Prieto JF, Dios E, Gutierrez JM, et al. Pars planitis: epidemiology, treatment, and association with multiple sclerosis. Ocul Immunol Inflamm. 2001;9:93.PubMedCrossRef
19.
Obenauf CD, Shaw HE, Sydnor CF, Klintworth GK. Sarcoidosis and its ophthalmic manifestations. Am J Ophthalmol. 1978;86:648.PubMed
20.
21.
Jabs DA, Johns CJ. Ocular involvement in chronic sarcoidosis. Am J Ophthalmol. 1986;102:297–301.PubMed
22.
23.
Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease. Lancet 1990;335:1078.
24.
25.
Atmaca LS. Fundus changes associated with Behçet's disease. Graefe's Arch Clin Exp Ophthalmol. 1989;227:340–4.CrossRef
26.
Masuda K, Inaba G, Mizushima II. A nationwide survey of Behcet’s disease in Japan. Jpn J Ophthalmol. 1974;19:278–85.
27.
Okada AA, Goto H, Ohno S, Mochizuki M, Ocular Behçet's Disease Research Group Of Japan. Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Arch Ophthalmol. 2012;130(5):592–8.PubMedCrossRef
28.
Rubsamen PE, Gass JD. Vogt-Koyanagi-Harada syndrome. Clinical course, therapy, and long-term visual outcome. Arch Ophthalmol. 1991;109:682.PubMedCrossRef
29.
Zhang XY, Wang XM, Hu TS. Profiling human leukocyte antigens in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol. 1992;113:567.PubMed
30.
Snyder DA, Tessler HH. Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol. 1980;90:69–75.PubMed
31.
32.
Duke-Elder S, Perkins ES. Sympathetic ophthalmitis, in Duke-Elder S: Diseases of the uveal tract. Mosby: St Louis; 1966. p. 558–93.
33.
Rao NA, Forster DJ, Spalton DJ. Sympathetic ophthalmia. In: Podos SM, Yanoff M, editors. The uvea uveitis and intraocular neoplasms, vol. 2. USA: Mosby-Wolfe; 1995. p. 8.10–3. Chapter 8.
34.
Kilmartin DJ, Dick AD, Forrester JV. Prospective surveillance of sympathetic ophthalmia in the UK and Republic of Ireland. Br J Ophthalmol. 2000;84:259–63.PubMedCrossRef
35.
Watzke RC, Packer AJ, Folk JC, et al. Punctate inner choroidopathy. Am J Ophthalmol. 1984;98:572–84.PubMed
36.
Schlaegel Jr TF. Eye histoplasmosis. Ann Ophthalmol. 1979;11:1645–54.PubMed
37.
Gass JD. Acute posterior multifocal placoid pigment epitheliopathy. Arch Ophthalmol. 1968;80:177–85.PubMedCrossRef
38.
Sinan C, Thierry V, Jeffrey SR, Neil AB. Neurological manifestations of acute posterior multifocal placoid pigment epitheliopathy. Stroke. 1996;27:996–1001.CrossRef
39.
O’Halloran HS, Berger JR, Lee WB, et al. Acute multifocal placoid pigment epitheliopathy and central nervous system involvement. Nine new cases and a review of the literature. Ophthalmology. 2001;108:861–8.PubMedCrossRef
40.
Palestine AG, Nussenblatt RB, Chan CC, et al. Histopathology of the subretinal fibrosis and uveitis syndrome. Ophthalmology. 1985;92:838–44.PubMedCrossRef
41.
LeHoang P, Ozdemir N, Benhamou A, et al. HLA-A29.2 subtype associated with birdshot retinochoroidopathy. Am J Ophthalmol. 1992;113:33.PubMed
42.
Durrani K, Zakka FR, Ahmed M, Memon M, Siddique SS, Foster CS. Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease. Surv Ophthalmol. 2011;56(6):474–510.PubMedCrossRef
43.
Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492.PubMedCrossRef
44.
Miserocchi E, Modorati G, Foster CS. New treatments in noninfectious uveitis. Dev Ophthalmol Basel, Karger. 2012;51:1–6.CrossRef
45.
Heiligenhaus A, Miserocchi E, Heinz C, Gerloni V, Kotaniemi K. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology. 2011;50:1390–4.PubMedCrossRef
46.
Foster CS, Vitale AT. Immunosuppressive chemotherapy. In: Foster CS, Vitale AT, editors. Diagnosis and treatment of uveitis. 1st ed. Philadelphia, PA: WB Saunders; 2002. p. 177–214.
47.
48.
Sobrin L, Christen W, Foster CS. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology. 2008;115:1416–21.PubMedCrossRef
49.
Fauc AS, Doppman JL, Wolff SM. Cyclophosphamide-induced remissions in advanced polyarteritis nodosa. Am J Med. 1978;64:890–4.CrossRef
50.
Fosdick WM, Parsons JL, Hill DF. Long-term cyclophosphamide therapy in rheumatoid arthritis. Arthritis Rheum. 1968;11:151–61.PubMedCrossRef
51.
Martin-Suarez I, D’Cruz D, Mansoor M, et al. Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rhem Dis. 1997;56:481–7.CrossRef
52.
53.
Murphy CC, Greiner K, Plskova J, et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol. 2005;123:634–41.PubMedCrossRef
54.
Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005;52:2447.PubMedCrossRef
55.
Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005;123:903.PubMedCrossRef
56.
Kempen JH, Daniel E, Dunn JP, et al. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ. 2009;339:2480.CrossRef
57.
Okada AA, Goto H, Ohno S, Mochizuki M. Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. Arch Ophthalmol. 2012;13:592–8.
58.
Miserocchi E, Pontikaki I, Modorati G, Gattinara M, Meroni PL, Gerloni V. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmun Rev. 2011;11(1):35–9.PubMedCrossRef
Metadata
Title
Noninfectious Immune-Mediated Uveitis and Ocular Inflammation
Authors
Jennifer Pan
Manuj Kapur
Rex McCallum
Publication date
01-01-2014
Publisher
Springer US
Published in
Current Allergy and Asthma Reports / Issue 1/2014
Print ISSN: 1529-7322
Electronic ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-013-0409-1

Other articles of this Issue 1/2014

Current Allergy and Asthma Reports 1/2014 Go to the issue

AUTOIMMUNITY (TK TARRANT, SECTION EDITOR)

Role of “Western Diet” in Inflammatory Autoimmune Diseases

AUTOIMMUNITY (TK TARRANT, SECITON EDITOR)

Complexities in the Relationship Between Infection and Autoimmunity

AUTOIMMUNITY (TK TARRANT, SECTION EDITOR)

Autoimmunity in the Pathogenesis and Treatment of Keratoconjunctivitis Sicca

OCCUPATIONAL ALLERGIES (JA POOLE, SECTION EDITOR)

Irritant-Induced Asthma in the Workplace

IMMUNE DEFICIENCY AND DYSREGULATION (DP HUSTON, SECTION EDITOR)

Emerging Role of Human Basophil Biology in Health and Disease

AUTOIMMUNITY (TK TARRANT, SECTION EDITOR)

Utility of Immunologic Testing in Suspected Rheumatologic Disease